Article Sidebar

PDF (Tiếng Việt)
Published: 2023-01-30
Abstract Views: 536
Views PDF (Tiếng Việt): 260
DOI: https://doi.org/10.52852/tcncyh.v160i12V2.1256
Issue
Vol. 160 No. 12V2 (2022)
Section
Các bài báo
How to Cite
Cương, H. M. ., Thăng, V. H. ., & Hương, B. T. T. . (2023). 18. Factors affecting survival in non-polyp colon cancer stage II - III with mutation of KRAS gene. Journal of Medical Research, 160(12V2), 148-157. https://doi.org/10.52852/tcncyh.v160i12V2.1256

18. Factors affecting survival in non-polyp colon cancer stage II - III with mutation of KRAS gene

Hoang Minh Cuong, Vu Hong Thang, Bui Thi Thu Huong

Main Article Content

Abstract

Aim: To determine some factors affected the survival time. Patient and method: 93 patients were collected from National Cancer Hospital, VietDuc Hospital and BachMai Hospital  between  Jannuary 2016 and August 2020. The inclusion criteria: stage II - III colon cancer  according to the 8th edition of American Joint Committee on Cancer staging system, no accompanied polyp, mutated KRAS gene. The exclusion criteria: diagnosed second cancer, anamnesis about the removal of colorectal polyp. Results: The mean age was 53,9 ± 12,4 years. The rate of KRAS gene mutations in Exon 2 was 91,4% (85/93). Mean overall survival (OS) was 50,6 ± 2,3 months. Mean disease free survival (DFS) was 39,5 ± 2,6 months. 3-year DFS and 4-year OS were 48,8% and 63,0%. Patients with pT4 stage or node metastasis had shorter outcomes than patients with pT3 or  negative node. Left-sided tumors witnessed lower DFS compared with Right-sided tumors (3-year DFS 32,2% versus 62,4%, p = 0,006). Mutated KRAS gene in codon 12 or codon 13 was not a significant prognostic factor for disease-free survival or overall survival (3-year DFS: codon 12: 50,8% - codon 13: 61,9%, p = 0,419; 4-year OS: codon 12: 69,0% - codon 13: 70,7%, p = 0,584). Conclusions: Tumor invasion (pT4), positive node status (pN2) and left-sided tumor  were worse prognosis factors for survival. KRAS mutation codon 12 or 13 in Exon 2 did not affect to survival

Article Details

Keywords

colon cancer, Stage II-III, mutated KRAS, survival

References

1. Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. May 2021;71(3):209-249.
2. Pham Tung, Bui Linh, Kim Giang, Hoang Dong, Tran Thuan, Hoang Minh. Cancers in Vietnam-Burden and control efforts: A narrative scoping review. Cancer control: journal of the Moffitt Cancer Center. Jan-Dec 2019;26(1):1073274819863802.
3. Weiser MR. AJCC 8th Edition: Colorectal cancer. Annals of Surgical Oncology. June 01, 2018;25(6):1454-1455.
4. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. May 14, 2007;26(22):3291-3310.
5. Hoàng Anh Vũ, Hứa Thị Ngọc Hà. Phát hiện đột biến gen KRAS trong ung thư đại trực tràng bằng kỹ thuật COLD-PCR và giải trình tự DNA. Tạp chí Y học TP. Hồ Chí Minh. 2013;17(phụ bản số 3):tr.50-54.
6. Guo F, Gong H, Zhao H, et al. Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Scientific Reports. 2018;8(1):6076.
7. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clinical cancer research: An official journal of the American Association for Cancer Research. 2009;15(23):7322-7329.
8. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology. Jan 20 2010;28(3):466-474.
9. Bùi Ánh Tuyết, Nguyễn Văn Hiếu, Trần Văn Thuấn. Nghiên cứu một số đặc điểm lâm sàng, cận lâm sàng và tình trạng gen KRAS trong ung thư đại trực tràng. Tạp chí Ung thư học Việt Nam. 2014;2.
10. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. Journal of the National Cancer Institute. Nov 7 2012;104(21):1635-1646.
11. Shen Y, Han X, Wang J, et al. Prognostic impact of mutation profiling in patients with stage II and III colon cancer. Scientific reports. 2016;6:24310-24310.
12. Baek JH, Kim J, Baek DW, et al. Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer. Cancer diagnosis & prognosis. Jan-Feb 2022;2(1):78-83.
13. Cienfuegos JA, Baixauli J, Arredondo J, et al. Clinico-pathological and oncological differences between right and left-sided colon cancer (stages I-III): Analysis of 950 cases. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva. Mar 2018;110(3):138-144.
14. Jones RP, Sutton PA, Evans JP, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. British Journal of Cancer. 2017/03/01 2017;116(7):923-929.